A single-arm, single-center, exploratory clinical study of Iparomlimab and Tuvonralimab in combination with S-1 as first-line treatment for elderly patients ( >=75 years) with esophageal squamous cell carcinoma (ESCC)

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: 9da152e4eddb46905d5fd3e727ee90e68c2535bf
First added on: Oct 10, 2026